[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bausch & Lomb Corp (BLCO)

Bausch & Lomb Corp (BLCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,973,564
  • Shares Outstanding, K 357,057
  • Annual Sales, $ 5,101 M
  • Annual Income, $ -360,000 K
  • EBIT $ 477 M
  • EBITDA $ 916 M
  • 60-Month Beta 0.56
  • Price/Sales 1.17
  • Price/Cash Flow 9.98
  • Price/Book 0.92
  • Price/Earnings ttm 25.63
  • Earnings Per Share ttm 0.65
  • Most Recent Earnings $0.08 on 04/29/26
  • Next Earnings Date 07/29/26 [BMO]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    SIC-3851 Ophthalmic Goods

    Medical Services

Options Overview Details

View History
  • Implied Volatility 50.92% (+4.74%)
  • Historical Volatility 28.58%
  • IV Percentile 36%
  • IV Rank 13.48%
  • IV High 187.31% on 11/19/25
  • IV Low 29.66% on 05/12/26
  • Expected Move (DTE 7) 0.62 (3.82%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 119
  • Volume Avg (30-Day) 235
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 4,886
  • Open Int (30-Day) 5,042
  • Expected Range 15.61 to 16.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.16
  • Number of Estimates 5
  • High Estimate $0.21
  • Low Estimate $0.14
  • Prior Year $0.07
  • Growth Rate Est. (year over year) +128.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.65 +10.78%
on 06/17/26
17.46 -7.04%
on 07/07/26
+0.97 (+6.36%)
since 06/10/26
3-Month
14.65 +10.78%
on 06/17/26
17.46 -7.04%
on 07/07/26
-0.26 (-1.58%)
since 04/10/26
52-Week
13.09 +23.99%
on 07/31/25
18.92 -14.20%
on 02/25/26
+2.03 (+14.30%)
since 07/10/25

Most Recent Stories

More News
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today

Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today

BLCO : 16.23 (-2.99%)
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant...

BLCO.TO : 22.89 (-3.50%)
BLCO : 16.23 (-2.99%)
Bausch + Lomb Introduces Orphiaâ„¢, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

Designed to reduce the operational burden that stands between physicians and their patients. Initial offering focuses on pre-surgery cataract education, with additional AI capabilities...

BLCO.TO : 22.89 (-3.50%)
BLCO : 16.23 (-2.99%)
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July...

BLCO.TO : 22.89 (-3.50%)
BLCO : 16.23 (-2.99%)
1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off

1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off

BLCO : 16.23 (-2.99%)
HLIO : 80.03 (-0.07%)
SYBT : 76.26 (+0.58%)
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

Among dry eye sufferers who said their stress or anxiety levels were affected, most (73%) reported improvement following treatment While some sufferers (22%) were aware that dry eye symptoms...

BLCO.TO : 22.89 (-3.50%)
BLCO : 16.23 (-2.99%)
3 Small-Cap Stocks We Steer Clear Of

3 Small-Cap Stocks We Steer Clear Of

ASAN : 7.33 (-0.54%)
RIG : 5.20 (+1.17%)
BLCO : 16.23 (-2.99%)
1 Stock Under $50 to Own for Decades and 2 We Turn Down

1 Stock Under $50 to Own for Decades and 2 We Turn Down

DKNG : 26.48 (+0.70%)
FOUR : 50.81 (+3.08%)
BLCO : 16.23 (-2.99%)
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

Blink Triple Care Preservative Free eye drops are made with the same clinically proven formula as Blink Triple Care and provide up to 10 hours of dry eye symptom relief‡ ...

BLCO.TO : 22.89 (-3.50%)
BLCO : 16.23 (-2.99%)
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical...

BLCO.TO : 22.89 (-3.50%)
BLCO : 16.23 (-2.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R)....

See More

Key Turning Points

3rd Resistance Point 17.46
2nd Resistance Point 17.12
1st Resistance Point 16.67
Last Price 16.23
1st Support Level 15.88
2nd Support Level 15.54
3rd Support Level 15.09

See More

52-Week High 18.92
Fibonacci 61.8% 16.69
Last Price 16.23
Fibonacci 50% 16.00
Fibonacci 38.2% 15.32
52-Week Low 13.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.